The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report, Journal of Clinical Oncology, vol.27, issue.2, pp.289-297, 2009. ,
DOI : 10.1200/JCO.2008.16.6785
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma, Journal of Clinical Oncology, vol.27, issue.7, pp.1026-1033, 2009. ,
DOI : 10.1200/JCO.2008.16.0630
URL : https://hal.archives-ouvertes.fr/inserm-00369944
gene in advanced sporadic neuroblastoma tumours, Biochemical Journal, vol.416, issue.2, pp.153-159, 2008. ,
DOI : 10.1042/BJ20081834
URL : https://hal.archives-ouvertes.fr/hal-00479097
Oncogenic mutations of ALK kinase in neuroblastoma, Nature, vol.20, issue.7215, pp.971-974, 2008. ,
DOI : 10.1038/nature07399
Activating mutations in ALK provide a therapeutic target in neuroblastoma, Nature, vol.25, issue.7215, pp.975-978, 2008. ,
DOI : 10.1038/nature07397
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma, Nature, vol.40, issue.7215, pp.967-970, 2008. ,
DOI : 10.1038/nature07398
Identification of ALK as a major familial neuroblastoma predisposition gene, Nature, vol.25, issue.7215, pp.930-935, 2008. ,
DOI : 10.1038/nature07261
Molecular pathogenesis of peripheral neuroblastic tumors, Oncogene, vol.23, issue.11, pp.1566-1579, 2010. ,
DOI : 10.1158/0008-5472.CAN-06-4443
New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK, Clinical Cancer Research, vol.19, issue.21, pp.5814-5821, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0680
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma, Science Translational Medicine, vol.3, issue.108, pp.108-114, 2011. ,
DOI : 10.1126/scitranslmed.3002950
Targeting ALK in neuroblastoma???preclinical and clinical advancements, Nature Reviews Clinical Oncology, vol.23, issue.7, pp.391-399, 2012. ,
DOI : 10.1038/nrclinonc.2012.72
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study, The Lancet Oncology, vol.14, issue.6, pp.472-480, 2013. ,
DOI : 10.1016/S1470-2045(13)70095-0
High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number, Analytical Chemistry, vol.83, issue.22, pp.8604-8610, 2011. ,
DOI : 10.1021/ac202028g
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer, Clinical Cancer Research, vol.20, issue.10, pp.2643-2650, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2933
Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients, Cancer Res, vol.62, pp.3646-3648, 2002. ,
-Amplification in Neuroblastoma, Journal of Clinical Oncology, vol.23, issue.34, pp.8919-8920, 2005. ,
DOI : 10.1200/JCO.2005.04.0170
URL : https://hal.archives-ouvertes.fr/hal-01305344
amplification, Pediatric Blood & Cancer, vol.341, issue.3, pp.329-331, 2009. ,
DOI : 10.1002/pbc.22009
Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA, Pediatric Blood & Cancer, vol.22, issue.5, pp.757-761, 2011. ,
DOI : 10.1002/pbc.22816
URL : https://hal.archives-ouvertes.fr/hal-00788900
Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction, Journal of Clinical Oncology, vol.23, issue.22, pp.5205-5210, 2005. ,
DOI : 10.1200/JCO.2005.02.014
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project, European Journal of Cancer, vol.47, issue.4, pp.561-571, 2011. ,
DOI : 10.1016/j.ejca.2010.10.022
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment., Journal of Clinical Oncology, vol.11, issue.8, pp.1466-1477, 1993. ,
DOI : 10.1200/JCO.1993.11.8.1466
ROC (receiver operating characteristics) curve: principles and application in biology, Ann. Biol. Clin. (Paris), vol.63, pp.145-154, 2005. ,
Mutations at Relapse of Neuroblastoma, Journal of Clinical Oncology, vol.32, issue.25, pp.2727-2734, 2014. ,
DOI : 10.1200/JCO.2013.54.0674
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.15, issue.8, pp.2630-2636, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2592
Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids, PLoS ONE, vol.132, issue.10, p.77963, 2013. ,
DOI : 10.1371/journal.pone.0077963.s006
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma, Nature Genetics, vol.57, issue.1, pp.12-17, 2013. ,
DOI : 10.1038/ng.2493
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer, Arch. Pathol. Lab. Med, vol.133, pp.1600-1606, 2009. ,
Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing, Clinical Chemistry, vol.59, issue.1, pp.211-224, 2013. ,
DOI : 10.1373/clinchem.2012.196014
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <em>ALK</em>-mutated neuroblastoma, Oncotarget, vol.5, issue.18, pp.8737-8749, 2014. ,
DOI : 10.18632/oncotarget.2372